October 2024
Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug
Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease
GSK Shifts Focus from Acquired Vaccine to Preclinical Successor Due to Increased Competition
GSK, vaccine, preclinical successor, increased competition, pneumococcal vaccine, Affinivax, MAPS technology
Biotech Layoffs Continue in 2024: Spero and Pfizer Among Latest to Cut Workforce
Biotech layoffs, Spero, Pfizer, workforce reduction, 2024 layoffs, pharmaceutical industry, job cuts.
TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP
TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval
Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast
Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales
Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion
Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition
Lexicon’s Diabetes Drug Zynquista Faces FDA Scrutiny Again Ahead of Advisory Committee Meeting
Lexicon Pharmaceuticals, Zynquista, FDA, diabetes drug, advisory committee, regulatory challenges
Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure
Spero Therapeutics, antibiotic trial failure, workforce reduction, biotech layoffs, cash runway extension
Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae
Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction